Contribution of the Dawn Phenomenon to the Fasting and Postbreakfast Hyperglycemia In Type 1 Diabetes Treated With Once-Nightly Insulin Glargine

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Mauro Lepore, Simone Pampanelli, Carmine G. Fanelli et al. · Diabetes · 2000 · 820 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes Mellitus

Peter J. Campbell, Geremia B. Bolli, Philip E. Cryer et al. · New England Journal of Medicine · 1985 · 218 citations

Medicine, Endocrinology, Physiology +17

Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin

Francesca Porcellati, Paolo Rossetti, Simone Pampanelli et al. · Diabetic Medicine · 2004 · 129 citations

Medicine, Endocrinology, Internal Medicine +16

A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes

A. Hamann, S. Matthäei, Christoph Rosak et al. · Diabetes Care · 2003 · 125 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

Geremia B. Bolli, David Kerr, Reena Thomas et al. · Diabetes Care · 2009 · 119 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +15